A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIb Clinical Trial Evaluating the Efficacy and Safety of Mecasin (KCHO-1) in Adults with Amyotrophic Lateral Sclerosis
Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive muscle weakness and paralysis, with respiratory failure being the leading cause of death. Mecasin (KCHO-1), a standardized botanical extract, has demonstrated neuroprotective and anti-neuroinflammatory effects in preclinical studies. A 12-week phase IIa trial suggested a potential benefit in slowing functional decline. This phase IIb trial evaluated the efficacy and safety of Mecasin over 24 weeks, including respiratory-related outcomes. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 50 patients were randomized to receive Mecasin (2.4 g/day) or placebo for 24 weeks, with both groups receiving riluzole (100 mg/day). Forty-three patients were included in the efficacy analysis. The primary endpoint was change in the Korean version of the ALS Functional Rating Scale-Revised (K-ALSFRS-R) total score. Respiratory-related assessments included orthopnea, FEV1/FVC, and end-tidal CO2, alongside safety evaluations. Results: At week 24, K-ALSFRS-R changes were −3.65 and −3.74 points in the Mecasin and placebo groups, respectively, with no significant between-group difference (estimated difference, 0.27; 90% CI, −1.80 to 2.33; p = 0.4146). Significant between-group differences were observed in FEV1/FVC (7.69 percentage points; p = 0.0036) and end-tidal CO2 (−3.92 mmHg; p = 0.0076). Linear mixed-effects models showed significant group-by-visit interactions for orthopnea (p = 0.0212) and FEV1/FVC (p = 0.0228). Adverse-event frequencies were comparable. Conclusions: Although Mecasin did not show a significant effect on the primary outcome (K-ALSFRS-R total score), the observed differences in respiratory-related outcomes provide a clinical rationale for further investigation in larger trials focusing on respiratory function.
Source: Journal of Clinical Medicine
DOI: 10.3390/jcm15229076
Authors: Joonyoung Shin(Writing – original draft), Hyorin Lee(Writing – original draft), Tae Seong Jeong(Investigation), Eunhye Cha(Investigation), Wookcheol Seo(Investigation), Boncho Ku(Visualization), Ilhong Son(Investigation), Hyung Won Kang(Writing – review & editing), Dongwoung Kim(Investigation), Bongkeun Song(Investigation), Dongwoon Han(Writing – review & editing), Sungchul Kim(Conceptualization, Funding acquisition, Supervision, Writing – review & editing)
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,137
Awards: G4009494829, G5168813809
OpenAlex ID: W7236830554
